PASADENA, Calif.--(BUSINESS WIRE)--Osmetech plc (LSE:OMH) (“Osmetech” or the “Company”), the international molecular diagnostics company, announces that it has signed an agreement as principal supplier of Warfarin Sensitivity tests for a major new US trial sponsored by the US National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health (NIH) in the US.
